Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT
Language English Country England, Great Britain Media print-electronic
Document type Letter, Research Support, Non-U.S. Gov't
PubMed
32884117
DOI
10.1038/s41409-020-01045-4
PII: 10.1038/s41409-020-01045-4
Knihovny.cz E-resources
- MeSH
- Transplantation, Autologous MeSH
- Humans MeSH
- Neoplasm Recurrence, Local * MeSH
- Lymphoma, Non-Hodgkin * drug therapy MeSH
- Antineoplastic Combined Chemotherapy Protocols MeSH
- Treatment Outcome MeSH
- Salvage Therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Letter MeSH
- Research Support, Non-U.S. Gov't MeSH
Department of Cell Therapy Institute of Haematology and Blood Transfusion Prague Czech Republic
Department of Oncology Hospital České Budějovice České Budějovice Czech Republic
Department of Oncology University Hospital Motol Prague Czech Republic
See more in PubMed
Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–90. PubMed DOI PMC
Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32:3490–6. PubMed DOI
Davison K, Chen BE, Kukreti V, Couban S, Benger A, Berinstein NL, et al. Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial. Ann Oncol. 2017;28:622–7. PubMed DOI
van Imhoff GW, McMillan A, Matasar MJ, Radford J, Ardeshna KM, Kuliczkowski K, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017;35:544–51. PubMed DOI
Jantunen E, Canals C, Rambaldi A, Ossenkoppele G, Allione B, Blaise D, et al. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica. 2008;93:1837–42. PubMed DOI
Elstrom RL, Martin P, Hurtado Rua S, Shore TB, Furman RR, Ruan J, et al. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol. 2012;87:433–5. PubMed DOI
Chihara D, Izutsu K, Kondo E, Sakai R, Mizuta S, Yokoyama K, et al. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transpl. 2014;20:684–9. DOI
Dahi PB, Tamari R, Devlin SM, Maloy M, Bhatt V, Scordo M, et al. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transpl. 2014;20:2004–9. DOI
Sun L, Li S, El-Jawahri A, Armand P, Dey BR, Fisher DC, et al. Autologous stem cell transplantation in elderly lymphoma patients in their 70s: outcomes and analysis. Oncologist. 2018;23:624–30. PubMed DOI
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68. PubMed DOI PMC
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9. PubMed DOI PMC
Belada D, Trněný M, editors, Diagnostic and treatment procedures in patients with malignant lymphomas. 10th ed., Czech Lymphoma Study Group; 2018. https://www.lymphoma.cz/_uploads/attachments/KLS_guidelines_10_2018_3.pdf .
Graf SA, Vaughn JE, Chauncey TR, Storer BE, Gopal AK, Holmberg LA, et al. Comorbidities, alcohol use disorder, and age predict outcomes after autologous hematopoietic cell transplantation for lymphoma. Biol Blood Marrow Transpl. 2016;22:1582–7. DOI
